SAILING study (48-week data)

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Cahn P, Pozniak AL, Mingrone H, et al, on behalf of the extended SAILING Study Team

Lancet 2013; 382: 700–708.

Read the full publication

You will need to register to view the full publication.

Sign me up for an account

UK/DTGP/0037/16o Date of Prep March 2017